PRISM MarketView Emerging NextGen Tech Index Top Mover: Spectral AI
The PRISM Emerging NextGen Tech index is home to many small and micro-cap stocks making a name and impact in the world of emerging technology. Leading the way, up 12.75%, is Spectral (NASD: MDAI), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, particularly burn care and diabetic foot ulcers.
Spectral recently announced enrollment in a pivotal clinical study to validate its proprietary imaging technology for burn size and healing assessment. The trial will be conducted in U.S. burns centers and emergency departments among both adult and pediatric patients. The company expects to seek FDA marketing authorization for use of its technology in burn indications in 2025.
Combining AI and multispectral imaging technology, Spectral is working to revolutionize wound care with its DeepView predictive diagnostic system, which offers an immediate assessment of a wound’s healing potential prior to treatment or medical intervention. In addition to “exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.”
For more information on Spectral and other top emerging tech movers, visit https://demo4.limegoat.com/index/prism-emerging-nextgen-tech/
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView system. DeepView is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
